Article
Biochemistry & Molecular Biology
Kathleen M. McClain, Joshua N. Sampson, Jessica L. Petrick, Kaitlyn M. Mazzilli, Robert E. Gerszten, Clary B. Clish, Mark P. Purdue, Loren Lipworth, Steven C. Moore
Summary: This study found that six serum metabolites were associated with the risk of kidney cancer, and three of these metabolites had independent associations in the mutually adjusted model. These metabolites may point to new biological pathways relevant to kidney malignancy.
Article
Biochemistry & Molecular Biology
In-Ho Kim, Hyo Jin Lee
Summary: Approximately 400,000 patients are diagnosed with kidney cancer annually worldwide, resulting in approximately 170,000 deaths. Clear cell RCC is the most common subtype, accounting for about 85% of metastatic RCC cases. Immunotherapy with checkpoint inhibitors has shown promising results and become the standard of care for advanced clear cell RCC.
Article
Surgery
James Hill
Summary: This study compared the efficacy and safety of endoluminal stenting and emergency surgery for patients with left-sided colonic obstruction caused by carcinoma. The results showed that stenting can reduce stoma formation.
BRITISH JOURNAL OF SURGERY
(2022)
Review
Oncology
Adam M. Kase, Daniel J. George, Sundhar Ramalingam
Summary: Biological discoveries in the past two decades have revolutionized the treatment of renal cell carcinoma. The development of agents targeting pro-angiogenic pathways and immunogenicity have significantly impacted the management of clear cell renal cell carcinoma. Clear cell is the most common subtype, and therapies have focused on the Von Hippel Lindau gene alterations, leading to the approval of tyrosine kinase inhibitors and immune checkpoint inhibitors. Combinations of these treatments have become the standard of care for advanced clear cell renal cell carcinoma, with promising new therapeutic targets under development.
Article
Oncology
Kevin T. Lynch, Gabriella C. Squeo, William J. Kane, Max O. Meneveau, Gina Petroni, Walter C. Olson, Kimberly A. Chianese-Bullock, Craig L. Slingluff, Eugene F. Foley, Charles M. Friel
Summary: Checkpoint-blockade therapy (CBT) is approved for select colorectal cancer (CRC) patients, but additional immunotherapeutic options are needed. Vaccination with carcinoembryonic antigen (CEA) and Her2/neu (Her2) peptides was found to be well tolerated and immunogenic in participants with advanced CRC. Adverse events were mainly mild, with 70% of participants showing immune response to the peptides and a median overall survival of 16 months. Further study is warranted to assess the clinical benefits of vaccination in advanced CRC.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Cell Biology
Ziad Bakouny, Ananthan Sadagopan, Praful Ravi, Nebiyou Y. Metaferia, Jiao Li, Shatha AbuHammad, Stephen Tang, Thomas Denize, Emma R. Garner, Xin Gao, David A. Braun, Laure Hirsch, John A. Steinharter, Gabrielle Bouchard, Emily Walton, Destiny West, Chris Labaki, Shaan Dudani, Chun-Loo Gan, Vidyalakshmi Sethunath, Filipe L. F. Carvalho, Alma Imamovic, Cora Ricker, Natalie Vokes, Jackson Nyman, Jacob E. Berchuck, Jihye Park, Michelle S. Hirsch, Rizwan Haq, Gwo-Shu Mary Lee, Bradley A. McGregor, Steven L. Chang, Adam S. Feldman, Catherine J. Wu, David F. McDermott, Daniel Y. C. Heng, Sabina Signoretti, Eliezer M. Van Allen, Toni K. Choueiri, Srinivas R. Viswanathan
Summary: This study comprehensively defines the clinical and molecular features of translocation renal cell carcinoma (tRCC), a subtype of kidney cancer driven by MiT/TFE gene fusions. tRCCs mainly harbor MiT/TFE fusions and homozygous deletions at chromosome 9p21.3, and display a heightened NRF2-driven antioxidant response. Patients with tRCC treated with vascular endothelial growth factor receptor inhibitors (VEGFR-TKIs) have worse outcomes compared to those treated with immune checkpoint inhibitors (ICI). The study findings may inspire new therapeutic hypotheses for tRCC.
Review
Oncology
Congwang Zhang, Lijun Li, Yipeng Zhang, Changchun Zeng
Summary: HLRCC is a rare hereditary cancer syndrome caused by mutations in the FH gene, with no standardized treatment currently available. The molecular mechanisms of how FH inactivation leads to HLRCC are discussed, along with potential therapeutic pharmacological strategies for prevention and treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
S. A. van Laar, K. B. Gombert-Handoko, R. H. H. Groenwold, T. van der Hulle, L. E. Visser, D. Houtsma, H. J. Guchelaar, J. Zwaveling
Summary: This study retrospectively reviewed the electronic health records of mRCC patients from two large hospitals in the Netherlands using text mining software. The study found that pazopanib and sunitinib were the most common first-line treatment options in real-world clinical practice, and patients' overall survival and progression-free survival were likely better than in clinical trials, possibly due to extensive follow-up treatments.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Immunology
Yukang Lu, Mengting Zhang, Jiajun Zhou, Xiulan Liu, Lanfeng Wang, Xinyi Hu, Yiping Mao, Rongfa Gan, Zhiping Chen
Summary: This review provides an overview of recent studies on the role of extracellular vesicles (EVs) in the progression of renal cell carcinoma (RCC), including their involvement in tumor cell interaction with M2 macrophages, mediating immune tolerance, and acting as communication messengers in the tumor microenvironment. The review also discusses the potential use of engineered sEVs or EV tumor vaccines, mesenchymal stem cell EV therapy, and reduction of tumor-derived EV secretion in RCC treatment. Overall, the review highlights the importance of EVs in RCC and their potential as a pathway for future treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Editorial Material
Oncology
Elizabeth P. Henske, Liang Cheng, A. Ari Hakimi, Toni K. Choueiri, David A. Braun
Summary: Chromophobe renal cell carcinoma (ChRCC) is the second most common variant of non-clear cell renal cell carcinoma. ChRCC differs from clear cell RCC (ccRCC) in terms of genetics, genomics, metabolism, cell of origin, and response to targeted and immune therapies. The pathogenesis of ChRCC is not well understood, but current evidence suggests two potential mechanisms: mTORC1 hyperactivation through PTEN pathway mutations and mitochondrial dysfunction leading to oxidative stress.
Article
Oncology
Preeti Kanikarla Marie, Cara Haymaker, Edwin Roger Parra, Young Uk Kim, Rossana Lazcano, Swati Gite, Daniele Lorenzini, Ignacio I. Wistuba, Rebecca S. Slack Tidwell, Xiaofei Song, Wai Chin Foo, Dipen M. Maru, Yun Shin Chun, Andy Futreal, Bryan Kee, David Menter, Luisa Solis, Ching-Wei Tzeng, Christine Parseghian, Kanwal Raghav, Van Morris, Chia-Chi Chang, Robert Jenq, Alda Tam, Chantale Bernatchez, Scott Kopetz, Jean-Nicolas Vauthey, Michael J. Overman
Summary: This study investigates the feasibility and safety of combining anti-CTLA-4 and anti-PD-L1 therapy in the preoperative management of resectable colorectal cancer liver metastases. Following treatment, evidence of T- and B-cell activation was seen in some patients, possibly contributing to prolonged relapse-free survival.
CLINICAL CANCER RESEARCH
(2021)
Article
Immunology
Xinglin Chen, Tongtong Zhang, Xinyu Zhai, Zhong Wan, Minyao Ge, Chengzong Liu, Mingyue Tan, Dongliang Xu
Summary: This study aimed to develop an mRNA vaccine for renal cell carcinoma (RCC) and determine the immune subtypes of RCC. The study identified 13 immune-related genes that could be targets for immunotherapy in RCC patients, and identified DBH-AS1 as a potential antigen for developing an mRNA vaccine.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Xinyi Hu, Yukang Lu, Jiajun Zhou, Lanfeng Wang, Mengting Zhang, Yiping Mao, Zhiping Chen
Summary: Colorectal cancer is a prevalent malignant tumor with high mortality and incidence rates. Small extracellular vesicles (sEVs) play a significant role in the communication and progression of cancer cells. Regulatory RNAs have emerged as potential biomarkers for the diagnosis and prognosis of colorectal cancer, influencing various cancer-related processes. This review highlights the importance of sEVs as biomarkers in colorectal cancer diagnosis and suggests their potential application in treatment, emphasizing the need for further research.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Oncology
Teak Jun Shin, Cheryn Song, Chang Wook Jeong, Cheol Kwak, Seongil Seo, Minyong Kang, Jinsoo Chung, Sung-Hoo Hong, Eu Chang Hwang, Jae Young Park, Hakmin Lee
Summary: Metastatic renal cell carcinoma to the pancreas (PM-RCC) is infrequent in Korean patients, and compared to other mRCC, PM-RCC demonstrates a favorable prognosis. Pancreas metastasectomy is associated with prolonged survival, especially in metachronous PM-RCC.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Urology & Nephrology
Raquibul Hannan, Mark F. McLaughlin, Laurentiu M. Pop, Ivan Pedrosa, Payal Kapur, Aurelie Garant, Chul Ahn, Alana Christie, James Zhu, Tao Wangg, Liliana Robles, Deniz Durakoglugil, Solomon Woldu, Vitaly Margulis, Jeffrey Gahan, James Brugarolas, Robert Timmerman, Jeffrey Cadeddu
Summary: This study investigates the efficacy of stereotactic ablative radiation (SAbR) in the management of primary renal cell carcinomas (RCCs). The results showed that SAbR was able to effectively control tumor growth and prevent progression in all patients. This non-invasive alternative has potential in the treatment of RCCs.
